http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 23 Oct 2024 00:50:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Press+Releases/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369 http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html <p> DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ligachembio.com%2Findex.php%3Flang%3De&amp;esheet=54140882&amp;newsitemid=20241022716600&amp;lan=en-US&amp;anchor=LigaChem+Biosciences%2C+Inc.&amp;index=1&amp;md5=3222c19a4d361b1e595994a81fc839a7" shape="rect">LigaChem Biosciences, Inc.</a> (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of Rodrigo Ruiz Soto, M.D., as Chief Medical Officer (CMO). Dr. Ruiz Soto will play a pivotal role in driving the company’s clinical strategy and advancing its robust pipeline of therapeutic candidates. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241022716600/en/" rel="nofollow">https://www.businesswire.com/news/home/20241022716600/en/</a></p><div id="bwbodyimg" style="width: 435px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241022716600/en/2281317/4/official_Dr._Rodrigo_Ruiz_Soto.jpg" alt="Dr. Rodrigo Ruiz Soto, newly appointed CMO of LigaChem Biosciences. (photo: http://www.streetinsider.com/Business+Wire/LigaChem+Biosciences+Appoints+Rodrigo+Ruiz+Soto+as+Chief+Medical+Officer/23866437.html Wed, 23 Oct 2024 00:50:00 -0400 141080 A.02073006 A.50114027 O.00008106 O.05741383 O.21549369